The Securities and Exchange Commission’s (SEC) expanding interpretation of insider trading laws is to face its first significant test in a San Francisco court on March 25, 2024. Typically, the concept of insider trading has revolved around the act where an employee, privy to confidential information, buys their own company’s stocks ahead of a public announcement that could boost prices. The upcoming litigation introduces a novel theory: what if the employee buys a rival company’s stock, speculating it will also rise?
According to a report by Bloomberg Law, the lawsuit involves the SEC accusing a former biopharmaceutical executive of illegally trading a competitor’s stock. The executive was charged with insider trading; however, in this case, the trades were not made in his own company’s shares but that of a rival company. This is based on the theory that the rival’s share value would also rise following the acquisition of his own company.
This case represents the SEC’s first endeavor at prosecuting so-called “shadow trading”, marking a significant deviation from standard insider trading cases. Should the court side with the SEC, it can potentially set a new precedent for insider trading regulation, shifting the boundaries of what can be considered illegal insider trading. Conversely, a decision against the SEC might limit the agency’s capability to broaden its regulatory reach.
This litigation has become a focal point for securities traders and lawyers as it could potentially redefine the boundaries of insider trading and stir a sea change in the securities enforcement landscape. Thus, it is likely that professionals in the field will be monitoring the trial and its outcome closely.